Sep, 2009

U.S.A.
News / Corporate
U.S. Patent and Trademark Office Issues a Notice of Allowance in OSI Pharmaceuticals' Reissue Application on Tarceva(R) Composition of Matter Patent
MELVILLE, N.Y., Sep 17, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" in OSI's reissue...
Read More

Aug, 2009

U.S.A.
News / Corporate
Update on Astellas' Request for Rigorous Testing and Safety-Related Labeling for Anti-Rejection Medications
Astellas Pharma US, Inc. ("Astellas") announced today an update regarding the status of the request for emergency relief and preliminary injunction from the U.S. Food and Drug Administration's...
Read More
U.S.A.
News / Corporate
Astellas Seeks Rigorous Testing and Safety-Related Labeling for Anti-Rejection Medications
Astellas Pharma US, Inc. ("Astellas") announced today that the U.S. Food and Drug Administration (FDA) has substantially denied the company's Citizen Petition to ensure the safe and effective use...
Read More

Mar, 2009

U.S.A.
News / Corporate
Astellas to Terminate Offer for CV Therapeutics
Tokyo, Japan, March 16, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that it will terminate its $16.00 per share offer for CV Therapeutics, Inc. (Nasdaq: CVTX) and will not...
Read More

Feb, 2009

U.S.A.
News / Corporate
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 per Share in Cash
Tokyo, Japan, February 27, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all...
Read More